Phase 3 Muscular Dystrophy Trial, Recruiting NCT07608432 Sponsor: Dyne Therapeutics Condition: Muscular Dystrophy
Back to Muscular Dystrophy

Phase 3 Muscular Dystrophy Trial, Recruiting

NCT07608432
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a male who can walk and has been diagnosed with Duchenne muscular dystrophy (DMD), with a specific type of genetic change that could be helped by a treatment called "exon 51 skipping"
  • You are able to get up from the floor in under 10 seconds, and this was confirmed at two separate check-up appointments
  • You have been taking steroids (such as prednisolone or deflazacort) at a steady dose every day or on weekends for at least 6 months before joining, and you are expected to continue at that same dose during the study

Who may not be able to join:

  • You have taken medication that suppresses your immune system (other than steroids) in the last 3 months
  • You have used any medication (other than steroids) that could affect muscle strength or function in the last 3 months
  • Your treatment for heart failure has been changed in the last 3 months
  • You have received a drug called eteplirsen in the last week
  • You have received other exon-skipping treatments, dystrophin-modifying therapies, or a drug called zeleciment rostudirsen in the last 6 months
  • You have received a drug called givinostat in the last 3 months
  • You have ever received gene therapy at any point in your life

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +1-781-317-1919

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Dyne Therapeutics
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 December 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rise From Floor (RFF) velocity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov